Peek Health, founded in Braga in 2015, sells PeekMed, software that lets orthopaedic surgeons plan joint operations on 3D models before they cut. By January 2025 it said more than 35,000 surgeries had been planned with it by over 4,500 registered users, according to the company. Its EIC project targeted knee osteotomy, which the project said can let patients postpone or avoid a knee replacement but is complex to plan.

The European Innovation Council granted €2,287,922 towards PeekMedAuto, a €3.3 million project from November 2022 to October 2024 to automate that planning with machine learning. The objective promised "revenue exceeding €40 million by 2026" and cumulative profits of about €40 million. The final report says the software performs automatic bone segmentation, landmark detection and planning, validated in a retrospective pilot study at four hospitals in Portugal, France and Germany. Portugal's Iberinform puts the company's annual sales in a band of up to €2 million, with 26 to 50 employees.

€2.29MEIC grant, 70% of a €3.3M project
€40MRevenue promised by 2026
7FDA 510(k) clearances since 2018
≤ €2MAnnual sales band, per Iberinform

Company file

Legal entity
Peek Health, S.A., NIF 513369686, Braga
Founded
9 January 2015
CEO
João Pedro Ribeiro
Product
PeekMed pre-operative planning software
Offices
Braga; Weissach, Germany; United States
Investors
Grosvenor House of Investments, Portugal Ventures
EIC project
PeekMedAuto, 1 Nov 2022 to 31 Oct 2024, closed

Where Peek Health Stands Now

The FDA's 510(k) database lists seven clearances for Peek Health: 2018, 2022 and 2024, and four in 2025, the last on 22 December. In January 2026 the company announced clearance for automatic 2D-to-3D knee reconstruction from standard X-rays, which it said matches real anatomy with over 90% accuracy, according to ORTHOWORLD. It opened a US office in 2024. The only equity round we found disclosed is a €3 million Series A in 2021.

"More than 35,000 surgical plans have been created using PeekMed worldwide, demonstrating the impact of our technology across the globe."

João Pedro Ribeiro, CEO, PeekMed, January 2026

The Technology: Planning From an X-ray

PeekMed lets a surgeon position implants or plan bone cuts on a model of the patient's joint. The EIC project automated the steps a surgeon did by hand for knee osteotomy, and the report claims planning now takes "only a few seconds". It gives no accuracy figures from the four-hospital study. The company's own count shows knee osteotomies are a minority of the surgeries planned with PeekMed.

What the EIC Project Promised, and What CORDIS Shows

The technical promise was met: the automated planner works and was tested in a retrospective study. The commercial promise was not. The project told the EIC the automation would bring revenue above €40 million by 2026; Iberinform's band for the company's sales tops out at €2 million.

  1. Automated osteotomy planningDeliveredPer final report.
  2. Clinical pilotDeliveredFour hospitals, retrospective.
  3. US regulatory pathDeliveredFour FDA clearances in 2025.
  4. €40M revenue by 2026MissedSales band up to €2M.

The Money

Peek Health's disclosed funding is a €3 million Series A in 2021, led by Grosvenor House of Investments and Portugal Ventures, and the EIC grant. It does not publish revenue; the €40 million target in its EIC project was twenty times the top of the sales band it is listed in.

What Cannot Be Checked

Questions for the EIC

Peek Health's exact revenue and profit, how the €40 million target was assessed at evaluation, and the accuracy results of the four-hospital study are not public.

Why Europe Should Care

The EIC funded a Portuguese company that has built a real product used in thousands of operations. It also accepted a revenue forecast that, on the available evidence, was far beyond reach, and that forecast formed part of the case for the grant.

What the project promised

Fully automated knee osteotomy planning, and revenue above €40 million by 2026.

What the record shows

The automation, a four-hospital pilot, seven FDA clearances, and sales of up to €2 million a year.

The Verdict

Good software, a forecast off twentyfold

Peek Health delivered the technology the EIC paid for and keeps winning clearances. Its revenue promise was off by a factor of twenty or more.

Peek Health and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.